Bio-Techne's Innovative Technology Facilitates FDA Approval of ZEVASKYN Gene Therapy Bio-Techne's Simple Western Technology has been pivotal in the FDA approval of ZEVASKYN, a groundbreaking gene therapy for RDEB patients, promoting advancements in medical treatments.

Bio-Techne's Innovative Technology Facilitates FDA Approval of ZEVASKYN Gene Therapy #USA #Minneapolis #Bio-Techne #ZEVASKYN #RDEB

Abeona Therapeutics Emerges in Dystrophic Epidermolysis Bullosa Market with ZEVASKYN Approval Abeona Therapeutics has made a key entry into the dystrophic epidermolysis bullosa (DEB) market by gaining FDA approval for its innovative gene therapy, ZEVASKYN, aimed at treating RDEB.

Abeona Therapeutics Emerges in Dystrophic Epidermolysis Bullosa Market with ZEVASKYN Approval #United_States #Las_Vegas #ZEVASKYN #Abeona_Therapeutics #Dystrophic_Epidermolysis_Bullosa

Rare Diseases Weekly News – May 1st 2025 This Week in Rare Disease Breakthroughs 🧬 | Pivotal Approvals, New Orphan Drug Designations, AI-Driven Biomarkers and more!🧬 From the […] The post Rare Diseases Weekly News – May 1st 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Rare Diseases Weekly News – May 1st 2025 #News #elafibranor #ZEVASKYN #PDUFA #genetherapy Comment below!

Rare Diseases Weekly News – May 1st 2025 This Week in Rare Disease Breakthroughs 🧬 | Pivotal Approvals, New Orphan Drug Designations, AI-Driven Biomarkers and more!🧬 From the […] The post Rare Diseases Weekly News – May 1st 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Rare Diseases Weekly News – May 1st 2025 #News #elafibranor #ZEVASKYN #PDUFA #genetherapy Comment below!

Rare Diseases Weekly News – May 1st 2025 This Week in Rare Disease Breakthroughs 🧬 | Pivotal Approvals, New Orphan Drug Designations, AI-Driven Biomarkers and more!🧬 From the […] The post Rare Diseases Weekly News – May 1st 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Rare Diseases Weekly News – May 1st 2025 #News #elafibranor #ZEVASKYN #PDUFA #genetherapy Comment below!

FDA Approves ZEVASKYN: A Historic Advancement for EB Community and Autologous Gene Therapy In a groundbreaking step for the RDEB community, the FDA has approved ZEVASKYN, the first autologous gene therapy for this rare skin disorder. This momentous achievement offers new hope and treatment options.

FDA Approves ZEVASKYN: A Historic Advancement for EB Community and Autologous Gene Therapy #USA #New_York #Epidermolysis_Bullosa #ZEVASKYN #Abeona_Therapeutics

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) - ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure - - Approval based on the pivotal Phase 3 VIITAL™ study, showing ZEVASKYN resulted in...

$ABEO #ZEVASKYN approved by FDA....and #PRV granted! Given sunsetting of PRVs there could be an upside surprise to how much Abeona will sell it for.

finance.yahoo.com/news/u-fda-a...